EGFR and neoplasm: We investigated on the unexplored roles of CTLA-4 in tumor and NK cells, and on that of EGFR in the modulation of immune responses by testing new combinatorial treatments of ipilimumab with an anti-EGFR aptamer endowed with anti-tumor activity, and by generating for the first time a novel bispecific immunoconjugate, made up of these two compounds.